Breaking News Instant updates and real-time market news.

INFI

Infinity Pharmaceuticals

$1.24 /

+0.06 (+5.08%)

, BMY

Bristol-Myers

$65.24 /

-0.21 (-0.32%)

07:44
01/13/20
01/13
07:44
01/13/20
07:44

Infinity Pharmaceuticals offers 2020 IPI-549 development and financial guidance

Infinity Pharmaceuticals (INFI) sees MARIO-275, the company's ongoing global, randomized, controlled Phase 2 study in collaboration with Bristol-Myers Squibb (BMY), to evaluate IPI-549 in combination with Opdivo in platinum-refractory, I/O naive patients with advanced urothelial cancer, reporting data in mid-2021. MARIO-3, the company's ongoing Phase 2 study in collaboration with Roche/Genentech (RHHBY) to evaluate IPI-549 in novel triple combination front-line therapies with Tecentriq and Abraxane in triple negative breast cancer and with Tecentriq and Avastin in renal cell cancer, is seen reaching enrollment completion and initial data in 2020. The company also sees additional data from MARIO-1, the company's ongoing Phase 1/1b study of IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced solid tumors, in 2020. An ongoing Phase 1/1b trial, being conducted by Arcus (RCUS), is evaluating a checkpoint inhibitor-free, novel triple-combination regimen of IPI-549 + AB928 + Doxil in advanced TNBC patients. The trial has been initiated with a goal of enrollment of up to 40 patients in an expansion cohort. Infinity ended 2019 with approximately $42.4M in cash and investments and plans to report its fourth quarter and full-year 2019 financial results in March. The company said cash as of January 8, 2020 is about $62M, including $20M non-dilutive financing, it sees a net loss in 2020 of $40M-$50M and sees year-end cash of $15M-$25M.

INFI

Infinity Pharmaceuticals

$1.24 /

+0.06 (+5.08%)

BMY

Bristol-Myers

$65.24 /

-0.21 (-0.32%)

RHHBY

Roche

$0.00 /

+ (+0.00%)

RCUS

Arcus Biosciences

$10.04 /

-0.13 (-1.28%)

  • 13

    Jan

  • 27

    Jan

  • 30

    Jan

  • 06

    Feb

  • 10

    Feb

  • 13

    Feb

  • 10

    Mar

  • 25

    Mar

INFI Infinity Pharmaceuticals
$1.24 /

+0.06 (+5.08%)

06/26/19 OPCO
Infinity Pharmaceuticals initiated with an Outperform at Oppenheimer
11/18/19 RILY
Infinity Pharmaceuticals resumed with a Buy at B. Riley FBR
06/27/19
Fly Intel: Top five analyst initiations
06/27/19
Oppenheimer bullish on Infinity Pharmaceuticals, initiates with an Outperform
BMY Bristol-Myers
$65.24 /

-0.21 (-0.32%)

01/06/20 SBSH
Bristol-Myers upgraded to Buy from Neutral on resumption at Citi
01/10/20 HCWC
Amended Nektar, Bristol pact reflects bempeg limitations, says H.C. Wainwright
01/10/20 PIPR
Nektar update with Bristol-Myers 'positive all around,' says Piper Sandler
01/10/20 GSCO
Goldman keeps Sell on Nektar despite amended Bristol-Myers Squibb agreement
RHHBY Roche
$0.00 /

+ (+0.00%)

12/24/19 BERN
Sarepta DMD gene therapy worth at least $90 per share, says Bernstein
12/30/19 WBLR
William Blair says Wave 'disappointment' leaves Ionis, Roche in Huntington lead
12/26/19 SBSH
Sarepta partnership comes with attractive economics, says Citi
12/24/19 FBCO
Sarepta price target lowered to $185 from $190 at Credit Suisse
RCUS Arcus Biosciences
$10.04 /

-0.13 (-1.28%)

09/26/19 MZHO
Arcus Biosciences initiated with a Buy at Mizuho
09/26/19 MZHO
Arcus Biosciences initiated with a Buy at Mizuho
09/27/19
Fly Intel: Top five analyst initiations
11/12/19 RHCO
Arcus Biosciences initiated with a Buy at SunTrust

TODAY'S FREE FLY STORIES

General news
Treasury Action: yields have edged off intraday lows » 14:35
01/23/20
01/23
14:35
01/23/20
14:35

Treasury Action: yields…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Daimler plans to make 50,000 Mercedes EQC cars in 2020, Reuters reports » 14:25
01/23/20
01/23
14:25
01/23/20
14:25
DDAIF

Daimler AG

$0.00 /

+ (+0.00%)

Daimler said it intends…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Zynga call volume above normal and directionally bullish » 14:25
01/23/20
01/23
14:25
01/23/20
14:25
ZNGA

Zynga

$6.41 /

-0.1 (-1.54%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Citigroup municipal strategists to hold analyst/industry conference call » 14:25
01/23/20
01/23
14:25
01/23/20
14:25

Municipal Securities…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Earnings
Notable companies reporting before tomorrow's open » 14:22
01/23/20
01/23
14:22
01/23/20
14:22
AXP

American Express

$131.16 /

-0.4 (-0.30%)

, NEE

NextEra Energy

$259.78 /

-0.07 (-0.03%)

, SYF

Synchrony

$36.16 /

-0.265 (-0.73%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include NextEra Energy (NEE), consensus $1.50... American Express (AXP), consensus $2.01... Synchrony (SYF), consensus $1.07.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Notable companies reporting after market close » 14:21
01/23/20
01/23
14:21
01/23/20
14:21
ETFC

E-Trade

$46.05 /

-0.46 (-0.99%)

, SWKS

Skyworks

$127.80 /

+2.8 (+2.24%)

, DFS

Discover

$85.51 /

+0.145 (+0.17%)

, ISRG

Intuitive Surgical

$610.29 /

+0.06 (+0.01%)

, INTC

Intel

$63.49 /

+0.7 (+1.11%)

Notable companies…

Notable companies reporting after the market close, with earnings consensus, include Intel (INTC), consensus $1.25... Intuitive Surgical (ISRG), consensus$3.38... Discover Financial (DFS), consensus $2.24... Skyworks (SWKS), consensus $1.65... E-TRADE (ETFC), consensus 83c.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Piper lists 10 strategic M&A opportunities for Microsoft in 'defining' 2020 » 14:19
01/23/20
01/23
14:19
01/23/20
14:19
MSFT

Microsoft

$166.14 /

+0.44 (+0.27%)

, TWLO

Twilio

$120.89 /

+1.8 (+1.51%)

, WDAY

Workday

$184.00 /

+1.42 (+0.78%)

, CRM

Salesforce

$183.39 /

+0.67 (+0.37%)

, RNG

RingCentral

$197.85 /

+2.68 (+1.37%)

, ZEN

Zendesk

$86.21 /

+0.975 (+1.14%)

, COUP

Coupa Software

$164.92 /

-2.57 (-1.53%)

In a research note to…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Fly Intel: What to watch in credit card space earnings reports » 14:18
01/23/20
01/23
14:18
01/23/20
14:18
AXP

American Express

$131.19 /

-0.37 (-0.28%)

, V

Visa

$206.88 /

-1 (-0.48%)

, MA

MasterCard

$323.60 /

-0.8 (-0.25%)

American Express (AXP),…

American Express (AXP), MasterCard (MA), and Visa (V) are scheduled to report quarterly results on January 24, 29, and 30, respectively. What to watch for: 1. OUTLOOKS: During the company's last earnings call, American Express said it sees fourth quarter revenue growth up 8%-10%, and backed fiscal year 2019 adjusted earnings per share view of $7.85-$8.35, with consensus at $8.12. The company also said it sees double-digit earnings per share growth in fiscal year 2019, fiscal year 2020 adjusted earnings per share growth in the mid-teens, and fiscal year 2020 revenue growth low double digits. Meanwhile, back in October, MasterCard said it sees fiscal year 2019 revenue growth at "high end of low teens," fiscal year 2019 tax rate of approximately 18%, fiscal year 2019 adjusted OpEx growth in the "high end of single-digits," and fourth quarter adjusted OpEx growth in the "high single-digits." 2. FTC INVESTIGATION: In a regulatory filing, Visa confirmed that on November 4, 2019, the Bureau of Competition of the United States Federal Trade Commission requested that Visa provide, on a voluntary basis, documents and information for an investigation as to whether Visa's actions inhibited merchant choice in the selection of debit payments networks in potential violation of the Durbin Amendment to the Dodd-Frank Wall Street Reform and Consumer Protection Act. According to a report by Bloomberg, both Visa and MasterCard have drawn an inquiry by U.S. antitrust regulators over policies that can prohibit merchants from routing card transactions over alternative debit networks. At issue is whether the card companies and big debit card issuers are blocking retailers from routing certain mobile wallet payments and tap-to-pay transactions over alternative networks such as Pulse, NYCE and Star, sources told Bloomberg. 3. PLAID ACQUISITION: Last week, Visa announced it has signed a definitive agreement to acquire Plaid, for a total purchase consideration of $5.3B. The transaction is subject to regulatory approvals and other customary closing conditions. Visa will fund the transaction from cash on hand and debt issuance at the appropriate time. This transaction will have no impact on Visa's previously announced stock buyback program or dividend policy. The transaction is expected to close in the next three to six months. 4. DIVIDEND INCREASE: Mastercard announced late last year that its board had declared a quarterly cash dividend of 40c per share, a 21% increase over the previous dividend of 33c per share. The cash dividend will be paid on February 7, 2020 to holders of record of its Class A common stock and Class B common stock as of January 9, 2020. The board also approved a new share repurchase program, authorizing the company to repurchase up to $8B of its Class A common stock. The new share repurchase program will become effective at the completion of the company's previously announced $6.5B program. The company has approximately $300M remaining under the current program authorization. 5. ATTRACTIVE VALUATION: In a research note to investors last week, William Blair analyst Robert Napoli reiterated an Outperform rating on American Express after reviewing the company's monthly data and trends in retail sales. The analyst believes valuation for the stock is "attractive given outlook and relative metrics to S&P 500." While some investors seem concerned about 2020 guidance, Napoli noted that management is confident in its outlook for 8%-10% revenue growth and double-digit EPS growth in 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Technical Analysis
NASDAQ market internals summary » 14:17
01/23/20
01/23
14:17
01/23/20
14:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Technical Analysis
NYSE market internals summary » 14:16
01/23/20
01/23
14:16
01/23/20
14:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is average for…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Periodicals
Regeneron tells Bloomberg to apply technologies to new coronavirus » 14:14
01/23/20
01/23
14:14
01/23/20
14:14
REGN

Regeneron

$357.08 /

-2.1 (-0.58%)

A Regeneron spokeswoman…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
FX Action: USD-CAD » 14:10
01/23/20
01/23
14:10
01/23/20
14:10

FX Action: USD-CAD eased…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Stifel says continues to recommend buying Netflix shares on pullbacks » 14:08
01/23/20
01/23
14:08
01/23/20
14:08
NFLX

Netflix

$341.73 /

+15.68 (+4.81%)

, CMCSA

Comcast

$45.75 /

-1.75 (-3.68%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

Stifel analyst Scott…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Whiting Petroleum call volume above normal and directionally bullish » 14:05
01/23/20
01/23
14:05
01/23/20
14:05
WLL

Whiting Petroleum

$4.98 /

-0.095 (-1.87%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
HP says value creation not dependent on Xerox deal, blames Icahn for nominees » 14:01
01/23/20
01/23
14:01
01/23/20
14:01
HPQ

HP Inc.

$22.13 /

+0.2 (+0.91%)

, XRX

Xerox

$36.31 /

+ (+0.00%)

HP Inc. (HPQ) confirmed…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Wells Fargo to determine if further action appropriate after OCC actions » 13:58
01/23/20
01/23
13:58
01/23/20
13:58
WFC

Wells Fargo

$48.32 /

-0.25 (-0.51%)

In response to actions…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
HP says Xerox buyout proposal 'significantly undervalues' company  13:57
01/23/20
01/23
13:57
01/23/20
13:57
HPQ

HP Inc.

$22.11 /

+0.185 (+0.84%)

, XRX

Xerox

$36.27 /

-0.04 (-0.11%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
HP says Xerox board nominations 'self-serving tactic'  13:56
01/23/20
01/23
13:56
01/23/20
13:56
HPQ

HP Inc.

$22.11 /

+0.185 (+0.84%)

, XRX

Xerox

$36.27 /

-0.04 (-0.11%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Blue Prism price target raised to 2,000 GBp from 1,710 GBp at Jefferies » 13:55
01/23/20
01/23
13:55
01/23/20
13:55
BPRMF

Blue Prism Group

$0.00 /

+ (+0.00%)

Jefferies analyst Julian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
FX Action: » 13:55
01/23/20
01/23
13:55
01/23/20
13:55

FX Action: USD-JPY fell…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
DOJ requires ZF, Wabco to divest Wabco steering components unit to complete deal » 13:53
01/23/20
01/23
13:53
01/23/20
13:53
WBC

Wabco

$135.51 /

+0.12 (+0.09%)

The Department of Justice…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
NIAID developing Gilead's remdesivir as coronavirus antiviral, Bloomberg says » 13:48
01/23/20
01/23
13:48
01/23/20
13:48
GILD

Gilead

$63.44 /

-0.06 (-0.09%)

A possible vaccine to…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
FDA highlights cybersecurity vulnerabilities in certain GE telemetry servers » 13:48
01/23/20
01/23
13:48
01/23/20
13:48
GE

General Electric

$11.69 /

+0.31 (+2.73%)

The Food and Drug…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Karuna pullback on PureTech sale a buying opportunity, says Wells Fargo » 13:45
01/23/20
01/23
13:45
01/23/20
13:45
KRTX

Karuna Therapeutics

$98.59 /

-17.38 (-14.99%)

Wells Fargo analyst Jacob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Options
Novavax call volume above normal and directionally bullish » 13:45
01/23/20
01/23
13:45
01/23/20
13:45
NVAX

Novavax

$7.66 /

+0.58 (+8.19%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.